Lakeshore Biopharma (NASDAQ:LSB) Shares Down 1.4% – Here’s Why

Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) shares dropped 1.4% during trading on Tuesday . The stock traded as low as $3.47 and last traded at $3.50. Approximately 25,652 shares traded hands during mid-day trading, a decline of 6% from the average daily volume of 27,263 shares. The stock had previously closed at $3.55.

Lakeshore Biopharma Stock Down 1.4 %

The firm’s 50 day moving average price is $2.79. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 0.17.

Institutional Trading of Lakeshore Biopharma

A number of institutional investors have recently made changes to their positions in the stock. Barclays PLC bought a new stake in Lakeshore Biopharma during the 3rd quarter valued at $169,000. Hhlr Advisors LTD. bought a new position in shares of Lakeshore Biopharma during the third quarter valued at about $513,000. Finally, FMR LLC bought a new position in Lakeshore Biopharma during the 3rd quarter valued at approximately $803,000. Hedge funds and other institutional investors own 52.64% of the company’s stock.

Lakeshore Biopharma Company Profile

LakeShore Biopharma Co, Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.